ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancer

Li, Jianhua; Wu, Huanxian; Lv, Shidong; Quan, Dongling; Yang, Danni; Xu, Jiahuan; Chen, Boyu; Ou, Baofang; Wu, Shaoyu*; Wei, Qiang*南方医科大学
Die Pharmazie2022-2DOI: 10.1691/ph.2022.1948
3被引4阅读
引用收藏
分享

摘要

Background: Patients with prostate cancer often develop resistance to androgen deprivation therapy, a condition called castration-resistant prostate cancer (CRPC). Enzalutamide (MDV3100) can prolong the survival of patients with CRPC after chemotherapy, but similar to 50% of patients eventually relapse and develop resistance to MDV3100. Thus, it is necessary to explore new treatment methods to improve the therapeutic effect of MDV3100. Tyrosine kinases play an essential role in the pathogenesis of CRPC. Methods: MTT assay was used to detect the inhibitory effects of MDV3100 and tyrosine kinase inhibitor on prostate cancer cells. CompuSyn version 1.0 was used to calculate the combination index (CI) values using the Chou-Talalay method. Clone formation and EdU assay were used to detect the effect of afatinib combined with MDV3100 on the proliferation of 22Rv1 cells. RT-qPCR and Western blot were used to explore the mechanism of drug combination. The aim of the present study was to determine the effects of several tyrosine kinase inhibitors (TKIs) when used in combination with MDV3100 in vitro. Results: The results demonstrated that TKIs combined with MDV3100 exerted a synergistic effect on a variety of PCa cells. Afatinib combined with MDV3100 could suppress the proliferation and migration of 22RV1 cells, as well as cause their cell cycle arrest and apoptosis. Mechanistically, afatinib effectively reduced the protein expression levels of HER2 and HER3 and inhibited EGFR phosphorylation, thereby enhancing the effect of MDV3100 and suppressing CRPC. Conclusions: These findings suggested that afatinib treatment improved the effect of MDV3100 on 22RV1 cells, highlighting this drug as a potential therapeutic strategy for patients with CRPC.

学科与关键词

关键词
ANDROGEN-RECEPTOR GENEPHASE-II TRIALTYROSINE PHOSPHATASECELL-PROLIFERATIONMECHANISMSENZALUTAMIDECOMBINATIONOVEREXPRESSION
相关
加载中…
  • IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
    Zhang, Yifan; Liao, Yuanpeng; Luo, Mayao; Ye, Yuedian; Xu, Zhuofan; Hou, Wenli; Liu, Ruiyu; Zhai, Qiliang; Lv, Shidong*; Wei, Qiang*PROSTATE, 2023, 83(15): 1446-1457.
  • Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
    Luo, Mayao; Zhang, Yifan; Xu, Zhuofan; Wu, Chenwei; Ye, Yuedian; Liu, Rui*; Lv, Shidong*; Wei, Qiang*Cell Death Discovery, 2022, 8(1): 471.被引 1
  • Regression of Castration-Resistant Prostate Cancer by a Novel Compound HG122
    Cong, Xiaonan; He, Yundong; Wu, Haigang; Wang, Dingxiang; Liu, Yongrui; Shao, Ting; Liu, Mingyao; Yi, Zhengfang; Zheng, Jianghua; Peng, Shihong*; Ding, Tao*Frontiers in Oncology, 2021, 11: 650919.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Die Pharmazie
发表日期
2022-02
卷期
第 77 卷, 第 2 期
页码
59-66
DOI
10.1691/ph.2022.1948
语言
MULTI-LANGUAGE
期刊等级
4区
成果收录
SCIE
资助标注
Natural Science Foundation of Guangdong Province, China [2018A030313405, 2021A1515011023]; Science and Technology Planning Project of Guangdong Province, China [2017A050501020]; National Natural Science Foundation of China [81872092]

作者

  • L

    Li, Jianhua (第一作者)

    southern med univ

  • W

    Wu, Huanxian

    new · southern med univ

查看全部 10 位作者收起作者
  • L

    Lv, Shidong

    southern med univ

  • Q

    Quan, Dongling

    new · southern med univ

  • Y

    Yang, Danni

    new · southern med univ

  • X

    Xu, Jiahuan

    new · southern med univ

  • C

    Chen, Boyu

    new · southern med univ

  • O

    Ou, Baofang

    new · southern med univ

  • W

    Wu, Shaoyu (通讯)

    new · southern med univ

  • W

    Wei, Qiang (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417